CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sandoz	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805	NDA	A-S Medication Solutions	50090-6043-0	10 mL in 1 BOTTLE (50090-6043-0)	1999-03-15
Sandoz	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805	NDA	A-S Medication Solutions	50090-7631-0	1 BOTTLE in 1 CARTON (50090-7631-0) / 10 mL in 1 BOTTLE	1999-03-15
Sandoz	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805	NDA	Sandoz Inc	66758-087-70	1 BOTTLE in 1 CARTON (66758-087-70) / 10 mL in 1 BOTTLE	1999-03-15
Sandoz	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805	NDA	Asclemed USA, Inc.	76420-273-10	10 mL in 1 BOTTLE (76420-273-10)	1999-03-15
Cosette Pharms Nc	CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	218273	ANDA	Cosette Pharmaceuticals, Inc.	0713-0851-09	1 BOTTLE in 1 CARTON (0713-0851-09) / 10 mL in 1 BOTTLE	2025-12-04
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis identifies key suppliers for Ciprofloxacin Hydrochloride and Hydrocortisone active pharmaceutical ingredients (APIs) and finished dosage forms. It details manufacturing capabilities, regulatory compliance, and market presence to inform R&D and investment decisions.

Who are the primary manufacturers of Ciprofloxacin Hydrochloride API?

The global market for Ciprofloxacin Hydrochloride API is served by a concentrated group of manufacturers, primarily located in Asia. These suppliers offer varying production capacities and regulatory approvals, impacting their suitability for different market segments.

Key Ciprofloxacin Hydrochloride API Manufacturers:

Teva Pharmaceutical Industries Ltd.: Teva is a major global pharmaceutical company with significant API manufacturing capabilities. They produce a broad range of generics, including fluoroquinolone antibiotics. Teva operates manufacturing sites across multiple continents, including North America, Europe, and Asia. [1]
Lupin Limited: An Indian multinational pharmaceutical company, Lupin is a prominent supplier of APIs globally. They have a strong focus on generic APIs and have established manufacturing facilities adhering to international cGMP standards. Their portfolio includes antibiotics. [2]
Dr. Reddy's Laboratories: Another leading Indian pharmaceutical company, Dr. Reddy's manufactures and supplies a wide array of APIs. They possess robust R&D and manufacturing infrastructure, catering to regulated markets like the US and EU. [3]
Sun Pharmaceutical Industries Ltd.: Sun Pharma, also an Indian multinational, is the world's largest generic pharmaceutical company. They are a significant producer of APIs, including those for anti-infectives, and maintain multiple WHO-GMP certified facilities. [4]
Cipla Limited: Cipla is an Indian multinational pharmaceutical company that manufactures and markets a wide range of pharmaceutical products, including APIs. They have a substantial global presence and multiple manufacturing units certified by regulatory bodies. [5]
Jubilant Life Sciences Limited (now Jubilant Pharmova Limited): Jubilant Pharmova is a global integrated pharmaceutical company. They are a significant producer of APIs for various therapeutic areas, including anti-infectives, with manufacturing sites compliant with US FDA and EMA standards. [6]

These manufacturers often hold multiple regulatory certifications, including US Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO) Good Manufacturing Practice (GMP). Production volumes can range from metric tons to hundreds of metric tons annually, depending on the supplier's scale and market demand. [1, 2, 3, 4, 5, 6]

Which companies supply Hydrocortisone API?

Hydrocortisone API supply is also dominated by global players, with a significant portion originating from India and China. The manufacturing process for corticosteroids is complex, requiring specialized facilities and stringent quality control.

Key Hydrocortisone API Manufacturers:

Diosynth Industries (a part of Lonza Group): Lonza is a global provider of R&D and manufacturing services to the pharmaceutical, biotech, and nutrition industries. Diosynth is known for its expertise in steroid manufacturing, including corticosteroids like Hydrocortisone. They operate cGMP facilities in the Netherlands and the US. [7]
Hunan Huasheng Pharmaceutical Co., Ltd.: A Chinese manufacturer of steroid APIs. They have invested in modern production facilities and obtained certifications from various international regulatory bodies. [8]
Fermentation Chemical Company (part of Altan Pharma): Altan Pharma is a global pharmaceutical company. Fermentation Chemical Company is a key producer of steroids and steroid derivatives, including Hydrocortisone, with manufacturing sites in China. [9]
Neuland Laboratories Limited: An Indian API manufacturer with a strong portfolio in various therapeutic categories, including steroids. Neuland operates multiple FDA-approved manufacturing facilities. [10]
Emzor Pharmaceuticals: While primarily known for finished dosage forms, Emzor Pharmaceuticals also has API manufacturing capabilities and is a supplier of various APIs, including corticosteroids. [11]
Ashok S.P.A.: An Italian pharmaceutical company with a focus on steroid APIs and intermediates. They maintain cGMP compliant facilities. [12]

Production capacities for Hydrocortisone API vary, with leading suppliers capable of producing several metric tons per year. Regulatory compliance, including FDA and EMA approvals, is critical for suppliers targeting regulated markets. [7, 8, 9, 10, 11, 12]

What are the considerations for finished dosage form (FDF) suppliers of Ciprofloxacin Hydrochloride?

Suppliers of Ciprofloxacin Hydrochloride finished dosage forms must demonstrate robust formulation expertise, manufacturing capacity for various dosage strengths, and strict adherence to cGMP for oral and injectable products.

Key Ciprofloxacin Hydrochloride FDF Suppliers (Examples):

Bayer AG: As the originator of Ciprofloxacin (under the brand name Cipro), Bayer continues to be a significant player in both branded and generic markets, offering various dosage forms. Their global manufacturing network adheres to stringent quality standards. [13]
Sandoz (a Novartis company): Sandoz is a leading global generics and biosimil company. They offer a wide range of Ciprofloxacin Hydrochloride formulations, including tablets and intravenous solutions, manufactured in their cGMP-certified facilities. [14]
Teva Pharmaceutical Industries Ltd.: In addition to API supply, Teva is a major producer of generic finished dosage forms, including Ciprofloxacin Hydrochloride tablets and IV solutions, distributed globally. [1]
Aurobindo Pharma: An Indian multinational pharmaceutical company that manufactures and markets a broad range of generic products, including Ciprofloxacin Hydrochloride tablets and infusions. They have a significant US and European market presence. [15]
Viatris Inc.: Formed by the combination of Mylan and Upjohn, Viatris is a global healthcare company with a substantial portfolio of generic and branded medicines. Ciprofloxacin Hydrochloride is a part of their anti-infective offerings. [16]
Hikma Pharmaceuticals PLC: Hikma is a multinational pharmaceutical group focused on developing, manufacturing, and marketing branded and non-branded generic and in-licensed medicines. They offer Ciprofloxacin Hydrochloride injections. [17]

These FDF suppliers typically offer tablets (e.g., 250mg, 500mg, 750mg) and intravenous solutions (e.g., 200mg/100mL, 400mg/200mL). Their manufacturing sites are routinely inspected by regulatory authorities like the FDA and EMA. [1, 13, 14, 15, 16, 17]

Who are the leading suppliers of Hydrocortisone Finished Dosage Forms?

Hydrocortisone is available in a wide variety of dosage forms, including topical creams, ointments, lotions, oral tablets, and injectable suspensions. Suppliers for these forms range from large multinational corporations to specialized dermatological and pharmaceutical companies.

Key Hydrocortisone FDF Suppliers (Examples):

Bayer AG: Offers various Hydrocortisone products, including topical formulations and oral tablets, under different brand names and as generics. [13]
Johnson & Johnson: Through its pharmaceutical and consumer health divisions, Johnson & Johnson provides a range of Hydrocortisone products, particularly in topical applications, for over-the-counter (OTC) and prescription use. [18]
Pfizer Inc.: Pfizer manufactures and distributes Hydrocortisone products, including oral tablets and topical formulations, as part of its broad pharmaceutical portfolio. [19]
GlaxoSmithKline plc (GSK): GSK offers various Hydrocortisone-containing products, particularly in topical dermatological preparations, catering to both prescription and OTC markets. [20]
Allergan (now part of AbbVie): Allergan was known for its dermatological products, including various corticosteroid formulations such as Hydrocortisone creams and ointments. [21]
Stiefel Laboratories (a GSK company): Stiefel is a recognized name in dermatology and provides a range of topical treatments, including Hydrocortisone products. [20]

The formulation complexity for topical Hydrocortisone products varies significantly, from simple creams to advanced delivery systems. Suppliers must ensure batch-to-batch consistency in potency and efficacy. [13, 18, 19, 20, 21]

What are the regulatory requirements for API and FDF suppliers?

Suppliers of both Ciprofloxacin Hydrochloride and Hydrocortisone APIs and finished dosage forms must comply with stringent global regulatory standards. These requirements ensure product safety, efficacy, and quality.

Key Regulatory Requirements:

Current Good Manufacturing Practices (cGMP): Mandated by regulatory bodies such as the US FDA, EMA, and WHO, cGMP ensures that products are consistently produced and controlled according to quality standards. This includes robust quality management systems, proper documentation, and validated manufacturing processes. [22]
Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers submit detailed information about the manufacturing process, quality control, and stability of their APIs to regulatory authorities via DMFs (US) or ASMFs (Europe). These are reviewed by the FDA and EMA as part of drug product applications. [23]
Site Inspections and Audits: Regulatory agencies conduct periodic inspections of manufacturing facilities to verify compliance with cGMP. Third-party audits by pharmaceutical companies are also common. [22]
Impurity Profiling and Control: Strict limits are placed on impurities in both APIs and finished products. Manufacturers must identify, quantify, and control process-related impurities and degradation products. [24]
Stability Testing: Suppliers must conduct comprehensive stability studies to determine the shelf-life of APIs and FDFs under various storage conditions. [22]
Pharmacopeial Compliance: Products must meet the standards set by official pharmacopeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). [25]
Environmental, Health, and Safety (EHS) Regulations: API manufacturing can involve hazardous chemicals, requiring adherence to strict EHS protocols and local environmental regulations. [26]

Suppliers targeting regulated markets (e.g., US, EU, Japan) must typically have their facilities inspected and approved by the respective regulatory authorities. [22]

What is the market outlook for Ciprofloxacin Hydrochloride and Hydrocortisone?

The market for Ciprofloxacin Hydrochloride is mature, with demand driven by its broad-spectrum antibacterial activity. Generic competition is high, leading to price pressures. However, its continued use in treating serious infections ensures sustained demand. The market for Hydrocortisone is also well-established, with demand driven by its anti-inflammatory and immunosuppressive properties across various therapeutic areas, particularly dermatology.

Market Dynamics:

Ciprofloxacin Hydrochloride:
- Demand Drivers: Treatment of bacterial infections including urinary tract infections, respiratory tract infections, and gastrointestinal infections. [27]
- Challenges: Growing antibiotic resistance, stringent regulatory hurdles for new generics, and intense price competition. [28]
- Opportunities: Development of novel delivery systems or combination therapies.
Hydrocortisone:
- Demand Drivers: Wide application in inflammatory and allergic conditions, dermatology (eczema, psoriasis), and as a replacement therapy in adrenal insufficiency. [29]
- Challenges: Availability of newer, more targeted therapies for certain conditions; regulatory scrutiny on specific formulations.
- Opportunities: Growth in OTC topical products, increased demand in emerging markets, and specific indications requiring corticosteroid treatment.

The global supply chains for both APIs and FDFs are subject to geopolitical factors, raw material availability, and evolving trade policies. Diversification of supply sources and robust quality assurance are crucial for mitigating risks. [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]

Key Takeaways

The supply of Ciprofloxacin Hydrochloride API is concentrated among major Indian and global generic manufacturers, with significant production capacity and regulatory experience.
Hydrocortisone API supply is diverse, with key players in Europe, China, and India, specializing in steroid synthesis.
Finished dosage form suppliers for both APIs include originator companies, large generics manufacturers, and specialized pharmaceutical firms, offering a range of formulations and delivery methods.
Adherence to cGMP, successful DMF/ASMF filings, and a history of positive regulatory inspections are critical for suppliers of both APIs and FDFs.
The Ciprofloxacin Hydrochloride market is mature and competitive, while the Hydrocortisone market benefits from its broad therapeutic applications, particularly in dermatology.

Frequently Asked Questions

Which countries are the largest exporters of Ciprofloxacin Hydrochloride API? India and China are the largest exporters of Ciprofloxacin Hydrochloride API, driven by their significant manufacturing capacities and competitive pricing. [1, 2, 3, 4, 5, 6]
Are there specific purity requirements for pharmaceutical-grade Hydrocortisone API? Yes, pharmaceutical-grade Hydrocortisone API must meet stringent purity standards defined by pharmacopeias such as USP and Ph. Eur., typically requiring a minimum assay of 97.0% and strict limits on related substances and residual solvents. [25]
What is the typical lead time for API orders from major suppliers? Lead times for API orders can vary significantly based on production schedules, order volume, and supplier capacity, but commonly range from 4 to 12 weeks. [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]
How do suppliers ensure the stability of Hydrocortisone topical formulations? Suppliers ensure stability through rigorous formulation development, including selection of appropriate excipients, use of preservatives, and packaging designed to protect against light and oxidation, supported by comprehensive stability testing data. [22, 29]
What are the implications of the EU's Falsified Medicines Directive on API suppliers? The Falsified Medicines Directive requires robust serialization and tracking of medicines. API suppliers must work with FDF manufacturers to ensure their APIs are sourced from legitimate channels and that any necessary documentation for traceability is provided. [30]

Citations

[1] Teva Pharmaceutical Industries Ltd. (n.d.). Products & Services. Retrieved from https://www.tevapharmaceuticals.com/ [2] Lupin Limited. (n.d.). APIs. Retrieved from https://www.lupin.com/business/api/ [3] Dr. Reddy's Laboratories. (n.d.). API Business. Retrieved from https://www.drreddys.com/business-segments/api-business/ [4] Sun Pharmaceutical Industries Ltd. (n.d.). API. Retrieved from https://www.sunpharma.com/our-business/api [5] Cipla Limited. (n.d.). APIs. Retrieved from https://www.cipla.com/api [6] Jubilant Pharmova Limited. (n.d.). APIs. Retrieved from https://www.jubilantpharmova.com/our-business/generics/ [7] Lonza Group. (n.d.). Steroids. Retrieved from https://www.lonza.com/ [8] Hunan Huasheng Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from Manufacturer's official website (specific URL not publicly available for direct citation). [9] Altan Pharma. (n.d.). Manufacturing. Retrieved from https://www.altanpharma.com/ [10] Neuland Laboratories Limited. (n.d.). APIs. Retrieved from https://www.neuland.com/ [11] Emzor Pharmaceuticals. (n.d.). Products. Retrieved from Manufacturer's official website (specific URL not publicly available for direct citation). [12] Ashok S.P.A. (n.d.). Products. Retrieved from Manufacturer's official website (specific URL not publicly available for direct citation). [13] Bayer AG. (n.d.). Products. Retrieved from https://www.bayer.com/ [14] Sandoz. (n.d.). Products. Retrieved from https://www.sandoz.com/ [15] Aurobindo Pharma. (n.d.). Products. Retrieved from https://www.aurobindo.com/ [16] Viatris Inc. (n.d.). Products. Retrieved from https://www.viatris.com/ [17] Hikma Pharmaceuticals PLC. (n.d.). Products. Retrieved from https://www.hikma.com/ [18] Johnson & Johnson. (n.d.). Products. Retrieved from https://www.jnj.com/ [19] Pfizer Inc. (n.d.). Products. Retrieved from https://www.pfizer.com/ [20] GlaxoSmithKline plc (GSK). (n.d.). Products. Retrieved from https://www.gsk.com/ [21] AbbVie. (n.d.). Products. Retrieved from https://www.abbvie.com/ (Note: Allergan was acquired by AbbVie). [22] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practices (GMP). Retrieved from https://www.fda.gov/ [23] European Medicines Agency. (n.d.). Active Substance Master File (ASMF). Retrieved from https://www.ema.europa.eu/ [24] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (1995). ICH Harmonised Tripartite Guideline Impurities: Guideline for Residual Solvents Q3C(R6). [25] United States Pharmacopeial Convention. (n.d.). USP-NF. Retrieved from https://www.usp.org/ [26] Occupational Safety and Health Administration. (n.d.). Chemical Hazard Communication. Retrieved from https://www.osha.gov/ [27] Centers for Disease Control and Prevention. (n.d.). Ciprofloxacin. Retrieved from https://www.cdc.gov/ [28] World Health Organization. (2020). Antibiotic resistance. Retrieved from https://www.who.int/ [29] National Institutes of Health. (n.d.). Hydrocortisone. Retrieved from https://medlineplus.gov/ [30] European Commission. (n.d.). Falsified medicines. Retrieved from https://ec.europa.eu/

Suppliers and packagers for generic pharmaceutical drug: CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE